Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVDL NASDAQ:DMAC NASDAQ:TSHA NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$15.22+1.5%$14.87$6.38▼$16.66$1.48B1.461.24 million shs1.04 million shsDMACDiaMedica Therapeutics$6.58-1.5%$6.46$3.19▼$7.49$340.11M1.4307,730 shs244,410 shsTSHATaysha Gene Therapies$4.72-7.1%$3.47$1.05▼$5.51$1.29B0.9911.84 million shs9.11 million shsZYMEZymeworks$18.40-0.8%$15.76$9.03▼$19.50$1.38B1.51544,658 shs446,971 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals0.00%+8.71%-6.22%+40.54%+14.95%DMACDiaMedica Therapeutics0.00%-0.90%-2.66%+57.42%+49.55%TSHATaysha Gene Therapies0.00%-3.28%+57.86%+83.66%+132.51%ZYMEZymeworks0.00%+1.88%+11.58%+29.12%+36.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$15.22+1.5%$14.87$6.38▼$16.66$1.48B1.461.24 million shs1.04 million shsDMACDiaMedica Therapeutics$6.58-1.5%$6.46$3.19▼$7.49$340.11M1.4307,730 shs244,410 shsTSHATaysha Gene Therapies$4.72-7.1%$3.47$1.05▼$5.51$1.29B0.9911.84 million shs9.11 million shsZYMEZymeworks$18.40-0.8%$15.76$9.03▼$19.50$1.38B1.51544,658 shs446,971 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals0.00%+8.71%-6.22%+40.54%+14.95%DMACDiaMedica Therapeutics0.00%-0.90%-2.66%+57.42%+49.55%TSHATaysha Gene Therapies0.00%-3.28%+57.86%+83.66%+132.51%ZYMEZymeworks0.00%+1.88%+11.58%+29.12%+36.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals 2.70Moderate Buy$20.8637.04% UpsideDMACDiaMedica Therapeutics 2.50Moderate Buy$12.3387.44% UpsideTSHATaysha Gene Therapies 2.80Moderate Buy$9.2595.97% UpsideZYMEZymeworks 3.00Buy$24.7534.51% UpsideCurrent Analyst Ratings BreakdownLatest DMAC, ZYME, AVDL, and TSHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/17/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.0010/17/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.0010/16/2025ZYMEZymeworksJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $23.0010/14/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral ➝ Buy$13.00 ➝ $26.0010/10/2025ZYMEZymeworksB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.0010/8/2025AVDLAvadel PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025DMACDiaMedica TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TSHATaysha Gene TherapiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025AVDLAvadel PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/2/2025TSHATaysha Gene TherapiesRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $12.0010/2/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $10.00(Data available from 10/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$169.12M8.74N/AN/A$0.77 per share19.77DMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.95 per shareN/ATSHATaysha Gene Therapies$8.10M159.00N/AN/A$0.35 per share13.49ZYMEZymeworks$122.87M11.26N/AN/A$6.63 per share2.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A253.67N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)DMACDiaMedica Therapeutics-$24.44M-$0.69N/AN/AN/AN/A-78.99%-69.94%11/12/2025 (Estimated)TSHATaysha Gene Therapies-$89.30M-$0.34N/AN/AN/A-1,144.97%-78.44%-44.82%11/12/2025 (Estimated)ZYMEZymeworks-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%11/6/2025 (Estimated)Latest DMAC, ZYME, AVDL, and TSHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025DMACDiaMedica Therapeutics-$0.15N/AN/AN/AN/AN/A11/12/2025Q3 2025TSHATaysha Gene Therapies-$0.09N/AN/AN/A$1.51 millionN/A11/11/2025Q3 2025AVDLAvadel Pharmaceuticals$0.08N/AN/AN/AN/AN/A11/6/2025N/AZYMEZymeworks-$0.28N/AN/AN/A$33.69 millionN/A8/12/2025Q2 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/A8/12/2025Q2 2025TSHATaysha Gene Therapies-$0.07-$0.09-$0.02-$0.09$1.61 million$1.99 million8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/7/2025N/AZYMEZymeworks-$0.52$0.03+$0.55N/A$17.18 million$48.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A2.792.38DMACDiaMedica TherapeuticsN/A7.557.55TSHATaysha Gene Therapies0.1712.4812.48ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%DMACDiaMedica Therapeutics10.12%TSHATaysha Gene Therapies77.70%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals5.20%DMACDiaMedica Therapeutics7.30%TSHATaysha Gene Therapies3.78%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableDMACDiaMedica Therapeutics2051.69 million47.92 millionOptionableTSHATaysha Gene Therapies180272.80 million262.48 millionOptionableZYMEZymeworks46075.17 million67.56 millionOptionableDMAC, ZYME, AVDL, and TSHA HeadlinesRecent News About These CompaniesZymeworks (NYSE:ZYME) Price Target Raised to $23.00October 19 at 2:57 AM | americanbankingnews.comJPMorgan ups Zymeworks target, places on ‘Positive Catalyst Watch’October 16 at 11:46 AM | msn.comWall Street Analysts Believe Zymeworks (ZYME) Could Rally 25.73%: Here's is How to TradeOctober 16 at 10:55 AM | zacks.comJPMorgan Chase & Co. Issues Positive Forecast for Zymeworks (NYSE:ZYME) Stock PriceOctober 16 at 8:08 AM | marketbeat.comWhat is HC Wainwright's Forecast for Zymeworks Q3 Earnings?October 16 at 6:52 AM | marketbeat.comZymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025October 16 at 6:00 AM | globenewswire.comHC Wainwright & Co. Upgrades Zymeworks (ZYME)October 14, 2025 | msn.comZymeworks Inc. (ZYME) is a Great Momentum Stock: Should You Buy?October 14, 2025 | zacks.comZymeworks (NYSE:ZYME) Shares Gap Up - Here's WhyOctober 14, 2025 | marketbeat.comZymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-?, at AACR-NCI-EORTC International ConferenceOctober 13, 2025 | tmcnet.comZymeworks Inc.: Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-?, at AACR-NCI-EORTC International ...October 13, 2025 | finanznachrichten.deZymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International ConferenceOctober 13, 2025 | globenewswire.comZymeworks (NYSE:ZYME) Stock Price Up 7.2% - Here's What HappenedOctober 11, 2025 | marketbeat.comEquities Analysts Set Expectations for Zymeworks Q3 EarningsOctober 11, 2025 | americanbankingnews.comLifesci Capital Forecasts Zymeworks' Q3 Earnings (NYSE:ZYME)October 10, 2025 | marketbeat.comZymeworks appoints Adam Schayowitz as Acting Chief Development OfficerOctober 9, 2025 | msn.comInMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of DirectorsOctober 9, 2025 | newsfilecorp.comNZymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development OfficerOctober 9, 2025 | globenewswire.comWhy Analysts See the Zymeworks Story Evolving After Key Pipeline and Market MovesOctober 8, 2025 | finance.yahoo.comQ1 Earnings Forecast for Zymeworks Issued By Lifesci CapitalOctober 8, 2025 | marketbeat.comPlatinum Investment Management Ltd. Decreases Stake in Zymeworks Inc. $ZYMEOctober 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDMAC, ZYME, AVDL, and TSHA Company DescriptionsAvadel Pharmaceuticals NASDAQ:AVDL$15.22 +0.22 (+1.47%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$14.99 -0.23 (-1.51%) As of 10/17/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.DiaMedica Therapeutics NASDAQ:DMAC$6.58 -0.10 (-1.50%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$6.71 +0.13 (+1.98%) As of 10/17/2025 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Taysha Gene Therapies NASDAQ:TSHA$4.72 -0.36 (-7.09%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$4.61 -0.11 (-2.44%) As of 10/17/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.Zymeworks NYSE:ZYME$18.40 -0.15 (-0.81%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$18.65 +0.25 (+1.36%) As of 10/17/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
